KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Finished Goods: 2018-2019

Historic Finished Goods for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Dec 2019 value amounting to $150.7 million.

  • Amneal Pharmaceuticals' Finished Goods was N/A to $222.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $222.2 million, marking a year-over-year change of. This contributed to the annual value of $150.7 million for FY2019, which is 31.93% down from last year.
  • Amneal Pharmaceuticals' Finished Goods amounted to $150.7 million in FY2019, which was down 31.93% from $221.4 million recorded in FY2018.
  • Amneal Pharmaceuticals' Finished Goods' 5-year high stood at $221.4 million during FY2018, with a 5-year trough of $150.7 million in FY2019.
  • Moreover, its 2-year median value for Finished Goods was $186.1 million (2018), whereas its average is $186.1 million.
  • Data for Amneal Pharmaceuticals' Finished Goods shows a maximum YoY plummeted of 31.93% (in 2019) over the last 5 years.
  • Over the past 2 years, Amneal Pharmaceuticals' Finished Goods (Yearly) stood at $221.4 million in 2018, then plummeted by 31.93% to $150.7 million in 2019.